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Abstract  35 
 36 
We recently demonstrated that cow’s milk fermented with the probiotic L.paracasei CBA L74 37 
(FM-CBAL74) reduces the incidence of respiratory and gastrointestinal tract infections in young 38 
children attending school. This effect apparently derives from a complex regulation of non-immune 39 
and immune protective mechanisms. We investigated wheter FM-CBAL74 could regulate gut 40 
microbiota composition and butyrate production.We randomly selected 20 healthy children (12-48 41 
months) from the previous randomized controlled trial, before (t0) and after 3 months (t3) of dietary 42 
treatment with FM-CBAL74 (FM), or placebo (PL). Fecal microbiota was profiled using 16S rRNA 43 
gene amplicon sequencing and fecal butyrate concentration was also measured. Microbial alpha and 44 
beta-diversity were not significantly different between groups prior to treatment. FM-CBAL74 but 45 
not PL treatment increased the relative abundance of Lactobacillus. Individual Blautia, Roseburia 46 
and Faecalibacterium oligotypes were associated to FM-CBAL74 treatment and demonstrated 47 
correlative associations with immune biomarkers. Accordingly, PICRUSt analysis predicted an 48 
increase in the proportion of genes involved in butyrate production pathways, consistent with an 49 
increase in fecal butyrate observed only in the FM group. Dietary supplementation with FM-50 
CBAL74 induces specific signatures in gut microbiota composition and stimulates butyrate 51 
production. These effects are associated with changes in innate and acquired immunity. 52 
Importance:  53 
The use of a fermented milk product containing the heat-killed probiotic strain L.paracasei 54 
CBAL74 induces changes in the gut microbiota, promoting the development of butyrate-producers. 55 
These changes in the gut microbiota composition correlate with increased levels of innate and 56 
acquired immunity biomarkers.57 
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Introduction  58 
Common infectious diseases, affecting respiratory and gastrointestinal tract, are an 59 
important problem for young children attending pre-school or day-care centers (1). Young children 60 
are especially prone to infection, and this susceptibility is thought to be driven by immaturity in 61 
organ function, immune response, and also potentially in the gut microbiota (2). Functional foods, 62 
based on the fermentation of cow’s milk with probiotics, have been proposed as an effective 63 
strategy to reduce the incidence infectious diseases in children, but the results are still conflicting 64 
(3-8). These discrepancies could derive mainly from different study designs and populations 65 
studies, and from different functional properties of the investigated fermented foods. The efficacy 66 
of fermented foods is believed to be strain-specific and dose-dependent. Therefore, additional 67 
research is required to understand the mode of action and the impact of each product, and clinical 68 
trials are needed to determine efficacy of claims in human populations.  69 
Bacteria associated with fermented foods may influence gut-associated microbial composition and 70 
function by direct competition, metabolic interaction, through direct immune activation, or via the 71 
production of bioactive molecules, such as the short chain fatty acid (SCFA), that are able to 72 
influence the host health regulating a number of immune and non-immune protective mechanisms  73 
(9-13). 74 
Many fermented foods are processed such that viable bacteria are inactivated at the time of 75 
consumption (9). Postbiotics containing dead bacterial cell have been shown to exert biological 76 
effects on the host immune system and to stimulate the production of anti-inflammatory cytokines 77 
(14-16). We previously demonstrated that a fermented cow’s milk product with heat-killed 78 
L.paracasei CBA L74 (FM-CBAL74) efficiently protects schooled children against respiratory and 79 
gastrointestinal tract infections, and that this protective effect is associated to a significant 80 
stimulation of innate and acquired immunity (17). 81 
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In order to assess the possible association of these effects with the structure of the gut microbiota, 82 
we designed this study to determine the effects of FM-CBAL74 treatment on gut microbiota 83 
composition and butyrate production. 84 
 85 
Methods 86 
Study subjects 87 
Detailed description of screening and recruitment of study population has been provided elsewhere 88 
(17). Briefly, consecutive healthy children (12-48 months of age) attending daycare or preschool at 89 
least five days a week, were invited to participate to the study. The exclusion criteria were: age ≤12 90 
months or ≥48 months, concomitant chronic systemic diseases, congenital cardiac defects, 91 
gastrointestinal or urinary or respiratory tract surgery, active tuberculosis, autoimmune diseases, 92 
immunodeficiency, chronic inflammatory bowel diseases, cystic fibrosis, metabolic diseases, 93 
history of suspected or challenge-proved food allergy, lactose intolerance, malignancy, chronic 94 
pulmonary diseases, malformations of gastrointestinal or urinary or respiratory tract, severe 95 
malnutrition (z score for weight-for-height <3 standard deviation scores), and use of 96 
pre/pro/synbiotics, antibiotics or immune stimulating products in the 2 weeks before the enrolment. 97 
From the original study population enrolled (17) we randomly selected 10 subjects per group 98 
through a random number generator (random.org, Randomness and Integrity Services Ltd., Dublin, 99 
Ireland). Anamnestic, demographic and clinical features, including innate and acquired immunity 100 
biomarkers data, as well as information regarding dietary habits, assessed by a 3-day food diary 101 
collected every week for the entire study duration, were available for the entire cohort (17). The 102 
sample size was calculated taking into account the size effect estimated from our previous data on 103 
butyrate levels (18).  We calculated that 10 children per group were needed to detect an increase of 104 
at least 50% above baseline mean fecal butyrate level with a power of 0.80 at an alpha level of 0.05 105 
(t-test for two independent samples with common variance two-tailed test). 106 
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The study was approved by the Ethics Committee of the University of Naples “Federico II” and was 107 
registered in the Clinical Trials Protocol Registration System (ClinicalTrials.gov) with the identifier 108 
NCT01909128. 109 
 110 
Intervention  111 
The investigators were blinded to the treatment at all times, i.e. allocation, intervention, laboratory 112 
analysis and statistical analysis (17). The study subjects were distributed into two groups according 113 
to a computer-generated randomization list. The investigators assigned each child the next available 114 
number on entry into the trial. Investigators, parents, and children were not aware of the dietary 115 
treatment assigned. Subjects were supplemented daily for 3 months with a dietary product deriving 116 
from cow’s milk fermented with L.paracasei CBA L74 (MILK), or placebo (PL).  117 
The composition of the dietary products used is reported in Table 1. They were provided in powder 118 
by Heinz Italia SpA, Latina, Italy, an affiliate of H.J. Heinz Company, Pittsburgh, PA, USA. The 119 
fermented milk was prepared from skimmed milk fermented by L.paracasei CBA L74. The 120 
fermentation was started in the presence of 10
6
 bacteria, reaching 5.9x10
9
CFU/g after a 15-hour 121 
incubation at 37°C. After heating at 85°C for 20 seconds in order to inactivate the live bacteria, the 122 
formula was spray-dried. Thus, the final fermented milk powder contained only bacterial bodies and 123 
fermentation products and no living microorganisms. The placebo consisted of maltodextrins with 124 
similar energy content of the fermented milk. Study products were provided in tins containing 400 g 125 
of powder, and the packaging was similar. Study products were stored at room temperature and in a 126 
dry environment. 127 
The FPs instructed parents about the daily amount of the assigned study product and the method of 128 
preparation. All subjects received 7 g/day of study products diluted in a maximum of 150 ml of 129 
cow’s milk or water. Parents were encouraged to contact the FP if necessary and to maintain the 130 
habitual diet of the child, but to exclude prebiotics, probiotics, postbiotics, synbiotics and immune 131 
stimulating products during the 3-month study period. 132 
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Compliance was defined as the consumption of at least 80% of the assigned treatment during the 133 
study and was evaluated by counting and weighingthe returned tins and by the notes on the diary 134 
compiled by parents. At the enrollment and at the end of the trial, a stool sample (about 3 g) was 135 
obtained from all study subjects and stored at -80 °C prior to further analysis. 136 
 137 
DNA extraction and 16S rRNA gene sequencing 138 
Fecal samples (about 1 g) were fully homogenized in STE buffer (100 mMNaCl, 10 mMTris-Cl pH 139 
8.0, 1 mM EDTA pH 8.0) and centrifuged (1,000 rpm x 1 min) in order to pellet debris. The 140 
supernatant was centrifuged again (12,000 x g, 2 min) and the pellet was used for DNA extraction, 141 
by using the PowerFecal DNA Isolation kit (Mo Bio Laboratories, Inc., Carlsbad, CA). The V3-V4 142 
region of the 16S rRNA gene was amplified by using primer S-D-Bact-0341F5’–143 
CCTACGGGNGGCWGCAG and S-D-Bact-0785R5’-GACTACHVGGGTATCTAATCC (19).  144 
Library multiplexing, pooling and sequencing were carried out following the Illumina 16S 145 
Metagenomic Sequencing Library Preparation protocol, on a MiSeq platform and using the MiSeq 146 
Reagent kit v2, leading to 2x250bp, paired-end reads. 147 
 148 
Bioinformatics and statistical analysis 149 
Demultiplexed, forward and reverse reads were joined by using FLASH (20). Joined reads were 150 
quality trimmed (Phred score < 20) and short reads (< 250 bp) were discarded by using Prinseq 151 
(21). High quality reads were then imported in QIIME (22). OTUs were picked through de novo 152 
approach and uclust method and taxonomic assignment was obtained by using the RDP classifier 153 
and the Greengenes (23) database, following a pipeline previously reported (24). In order to avoid 154 
biases due to the different sequencing depth, OTU tables were rarefied to the lowest number of 155 
sequences per sample. Bray Curtis distance matrix and alpha-diversity indices were computed by 156 
QIIME on rarefied OTU tables. PICRUSt (Phylogenetic Investigation of Communities by 157 
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Reconstruction of Unobserved States, http://picrust.github.io/picrust) (25) was used to predict the 158 
functional profiles of the samples, as recently reported (26). 159 
Statistical analyses and plotting were carried out in R environment (https://www.r-project.org). 160 
Permutational Multivariate Analysis of Variance (non-parametric MANOVA) based on Jaccard and 161 
Bray Curtis distance matrices was carried out by using 999 permutations to detect significant 162 
differences in the overall microbial community or oligotype patterns, by using the adonis function 163 
in vegan package. The Bioconductor statistical package DeSeq2 (27) was used to find taxa 164 
differentially abundant between the groups. Spearman’s pairwise correlations were computed 165 
between OTUs and other quantitative variables (corr.test function in psych package) and plotted by 166 
using the heatplot function in made4 package. P-values were corrected for multiple testing using 167 
Benjamini& Hochberg procedure (28).   168 
The 16S rRNA gene sequences produced in this study are available at the Sequence Read Archive 169 
(SRA) of the National Center for Biotechnology Information (NCBI), under accession number 170 
SRP100769. 171 
 172 
Oligotyping analysis 173 
Reads assigned to Bacteroides, and to genera within Ruminococcaceae and Lachnospiraceae, with 174 
abundance > 5% in at least 10% of the samples were extracted and entropy analysis and oligotyping 175 
were carried out (29). Only Bacteroides, Roseburia and Blautiaoligotype patterns were significantly 176 
affected by treatment. After the initial round of oligotyping, high entropy positions were chosen (-C 177 
option): 2, 27, 30, 31, 32, 94, 114, 120, 291 (Bacteroides); 1, 2, 12, 27, 28, 30, 56, 57, 58, 61, 82, 178 
101, 103, 157, 160, 170, 172, 174, 176, 184, 191, 213, 215, 220, 235, 237, 273, 274, 293, 343, 347, 179 
371, 409 (Blautia) and 2, 28, 57, 215, 272, 369, 370, 409, 410 (Roseburia). To minimize the impact 180 
of sequencing errors, we required an oligotype to be represented by at least 100 reads (-M option). 181 
Moreover, rare oligotypes present in less than 10 samples were discarded (-s option). These 182 
parameters led to 56, 59, 52 samples and 90,195/298,288/24,503 sequences left in Bacteroides, 183 
 o
n
 July 23, 2017 by CO
LUM
BIA UNIVERSITY
http://aem
.asm
.org/
D
ow
nloaded from
 
8 
 
Blautia and Roseburia datasets, respectively. BLASTn was used to query the representative 184 
sequences against the NCBI nr database, and the top hit was considered for taxonomic assignment. 185 
Statistical analyses and plotting were carried out in R. 186 
 187 
Fecal butyrate analysis 188 
One gram of frozen feces was diluted with saline buffer, vortexed and centrifuged (12,000 x g) for 189 
10 min in 2 ml tubes. The supernatant was filtered (0.45 μm) and stored at −20°C until analysis. 190 
Frozen fecal extracts were acidified with 20 μl of 85% (w/v) phosphoric acid and 0.5 ml of ethyl 191 
acetate, mixed, centrifuged (12,000 x g) for 1 h and extracted in duplicate. About 0.5 ml of the 192 
pooled extract containing the acidified butyrate was transferred into a 2 ml glass vial and loaded 193 
onto an Agilent Technologies (Santa Clara, CA, USA) 7890 gas chromatograph (GC) system with 194 
automatic loader/injector. The GC column was an Agilent J&W DB-FFAP (Agilent Technologies) 195 
of 30 m, internal diameter 0.25 mm and film thickness 0.25 μm. The GC was programmed to 196 
achieve the following run parameters: initial temperature 90°C, hold 0.5 min, ramp of 20°C min
−1
 197 
up to a final temperature of 190°C, total run time 8.0 min, gas flow 7.7 ml min
−1 
split less to 198 
maintain 3.26 p.s.i. column head pressure, septum purge 2.0 ml min
−1
. Detection was achieved 199 
using a flame ionization detector. Peaks were identified using a mixed external standard and 200 
quantified by peak height/internal standard ratio. 201 
 202 
Assessment of innate and acquired immunity biomarkers 203 
For all study subjects data related to fecal level of α-defensin (HNP 1-3), β-defensin 2 (HBD-2), 204 
cathelicidin (LL-37), and sIgA were available. The determinations were performed as previously 205 
described (17). The results were expressed as ng/g for α-defensin, β-defensin, and LL-37 and μg/g 206 
of supernatants for sIgA. 207 
 208 
Results 209 
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Study subjects 210 
The main features of the study populations are reported in Table 2. All children were from families 211 
of middle socioeconomic status from the same urban area. The dietary habits were very similar 212 
between the two study groups: energy (Kcal±SD) 1.420±51 vs 1.388±59; carbohydrates (gr±SD) 213 
225.9±7.3 vs 215.1±8; proteins (gr±SD) 31.8±2.7 vs 30.6±2.9; fats (gr±SD) 51.28±4.3 vs 51.46±4, 214 
fibers (gr±SD) 9.3±3.6 vs 11.9±2.7, in MILK and PL, respectively. All children were not febrile at 215 
inclusion and none was suffering from respiratory tract or gastrointestinal symptoms. The 216 
vaccination status was identical among the two groups. The interventions were well accepted by the 217 
children and the compliance was good in all study subjects. No differences were detected in the 218 
daily intake of the active and placebo products between the study groups. No modification of blood 219 
sugar and insulin levels were observed upon treatment. A significant increase in α-defensin (HNP 220 
1-3), β-defensin 2 (HBD-2), cathelicidin (LL-37) was observed only in children treated with FM 221 
CBAL74, as well as an increasing trend in sIgA (Figure S1). No difference in the average weighted 222 
Unifrac distance was found between MILK and PL at the beginning of the treatment (P>0.05). 223 
 224 
Effects of FM CBAL74 on gut microbiota composition  225 
We did not observe significant differences in alpha- and beta-diversity between children belonging 226 
to the two groups at the baseline (Figure S2 and S3). Treatment with FM CBAL74 affected gut 227 
microbiota composition. Although a great variability was observed, MANOVA showed significant 228 
differences in the gut microbiota composition between the two study groups following intervention 229 
(P<0.05). Nevertheless, Principal Coordinates Analysis (PCoA) did not show any clustering of the 230 
subjects according to the treatment received (Figure S3). The relative proportion of Lactobacillus 231 
and Ruminococcaceae significantly increased following FM-CBAL74 treatment (P<0.05), with 232 
specific significant increases in Oscillospira and Faecalibacterium (Table S1 and Figure 1, 233 
P<0.05). In addition, we found positive correlations between the relative abundance of several 234 
genera belonging to Ruminococcaceae and fecal LL-37 level, while Lachnospira and 235 
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Ruminococcus (Lachnospiraceae) correlated with HBD-2 levels (Figure 2). Gut microbiota of PL 236 
subjects was significantly different from FM-CBAL74 treated subjects after 3 months of treament, 237 
with significantly higher levels of Bacteroides (Table S1, P<0.05). 238 
 239 
Effect of fermented milk on gut microbiota at sub-genus level 240 
In order to explore the possible effect of FM CBAL74 at a sub-genus level, we carried out 241 
oligotyping on sequences of Bacteroides and genera belonging to Ruminococcaceae and 242 
Lachnospiraceae, since these bacterial groups are well-known butyrate-producers. Only 243 
Bacteroides, Blautia and Roseburia oligotype patterns showed significant changes after dietary 244 
intervention, as shown by MANOVA (p<0.05). Specific Roseburia oligotypes were promoted by 245 
FM CBAL74 treatment (Roseburia oligotype 1, Figure S4A) and showed positive correlations with 246 
sIgA (ρ=0.63, P=0.038) and beta-defensin (ρ=0.87, P=0.023). Blautia oligotypes 5 and 13 also 247 
increased with FM CBAL74 treatment,and were positively correlated with alpha-defensin (ρ=0.84, 248 
P=0.007; ρ=0.58, P=0.040) (Figure S4B). Finally, Bacteroides oligotypes 12 and 19 increased after 249 
FM CBAL74 treatment (Figure S4C), but only Bac12 (ρ=0.67, P=0.042) was positively correlated 250 
with alpha-defensin. 251 
 252 
FM CBAL74 treatment promotes butyrate production in the gut 253 
FM CBAL74 treatment resulted in an increase in the relative abundance of predicted genes 254 
involved in butyrate synthesis (PICRUSt predicted metagenomes), especially genes encoding 255 
butyrylcoA transferase (E.C 2.8.3.8) and butyrate kinase (E.C. 2.7.2.7)(Figure S5, P<0.05). 256 
Consistently, a significant increase in fecal butyrate levels in children consuming FM CBAL74 was 257 
observed (Figure 3, P<0.05). 258 
 259 
 260 
Discussion 261 
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It is increasingly understood that the outcomes of microbial fermentation provide additional 262 
properties to fermented foods beyond basic nutrition (9). During fermentation, the metabolic 263 
activity of microorganisms can change the nutritional and bioactive properties of food matrices with 264 
possible beneficial consequences for human health (9). The gut microbiota plays a key role in the 265 
development and function  of the immune system (30) and some of the health benefits of fermented 266 
foods could derive also from their impact on gut microbial composition and function (9). 267 
In a randomized controlled trial, we demonstrated that a cow’s milk fermented product containing 268 
the heat-killed probiotic strain  L. paracasei CBA L74 is effective in reducing the incidence  269 
respiratory and gastrointestinal tract infections in young children  (17). Interestingly, these results 270 
have been recently confirmed by a multicenter trial with a similar study design (31). Here we tested 271 
the effect of this  specific fermented product on gut microbiota composition and butyrate 272 
production. Distinctive traits of the gut microbiota, with increase of genera known as butyrate-273 
producers such as Oscillospira and Faecalibacterium (32,33), were observed in children receiving 274 
the fermented product. It has been previously shown that Faecalibacterium strains exert a 275 
stimulating effect on the immune system and on T-cells differentiation (34). In addition, an increase 276 
in Lactobacillus abundance was observed upon treatment with the fermented product, which is 277 
unlikely due to the presence of heat-killed lactobacilli in the fermented product, and more probably 278 
derives from a stimulatory effect of this product on such populations of lactic acid bacteria. 279 
We also demonstrated an effect of the fermented milk product beyond the genus level. In fact, 280 
specific oligotypes of Roseburia and Blautia were boosted by the treatment, suggesting an effect at 281 
sub-genus level, and highlighting a possible different effect of the fermented product on species and 282 
strains belonging to these genera, as previously pointed out for other common members of the gut 283 
microbiota (35,36). The dietary treatment resulted in an increase in the relative abundance of 284 
predicted genes involved in butyrate synthesis, especially genes encoding butyryl coA-transferase 285 
(E.C 2.8.3.8) and butyrate kinase (E.C. 2.7.2.7), and an associated significant increase in fecal 286 
butyrate levels likely deriving from lactate catabolism, one of the primary pathway for butyrate 287 
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production by gut bacteria (37). Altogether, these results suggest that a shift in the relative 288 
proportion of certain bacterial genera and oligotypes may be associated with an enhanced butyrate 289 
synthesis. Butyrate regulates several non-immune and immune defense mechanisms against 290 
infections, including: regulation of luminal pH in the gut, mucus production, cell growth and 291 
differentiaton, modulation of gut permeability and of transepithelial ion transport, modulation of the 292 
inflammatory response, stimulation of innate and acquired immunity (33,38-40). Although we 293 
investigated only butyrate, it cannot be excluded that also the production of other SCFAs could be 294 
regulated by this particular fermented product. 295 
We found positive correlations between specific gut microbiota signatures and fecal levels of innate 296 
and acquired immunity biomarkers. This data is in line with the results obtained using a fermented 297 
milk formula containing two heat-inactivated probiotic strains in pre-term infants (4).  298 
The results of this study support the concept of a mutualistic interaction occuring between gut 299 
microbiota and immune system, where gut microbiota influences immune system development and 300 
function, and the immune system shapes gut microbiota composition (41,42). It is possible to 301 
speculate that the effect of this particular fermented food on gut microbiota could derive at least in 302 
part by a modulation of innate immunity peptides. Indeed, evidence on the positive correlations 303 
between specific members of the gut microbiota and immunity peptides has been obtained in this 304 
study. The final result is the establishment and consolidation of a microbiota composition that can 305 
be responsible for a protective action against infectious diseases. In line with this view, we have 306 
recently demonstrated that, through a direct interaction with human enterocytes, FM CBAL74 307 
stimulates the synthesis of beta defensin 2 and LL-37 (43). Future studies are necessary to define 308 
the components of this particular fermernted product that are involved in this effects. In this light,  309 
comparison with different types of placebo, such as milk without the addition of bacteria or 310 
fermented by other lactobacilli, would provide useful information.  311 
It is important to recognise that this study investigated a dietary product fermented with a specific 312 
probiotic strain, a well-defined dose, and age group, and that our findings cannot be extrapolated for 313 
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other products containg different probiotic strains. Indeed, it cannot be excluded that similar results 314 
could be obtained with milk products fermented by phylogenetically close lactic acid bacteria. In 315 
this study, the similar dietary habits of treated and placebo groups strongly suggest that the effect 316 
observed on gut microbiota composition and butyrate production derive from the administration of 317 
the fermented milk used. In this study, children enrolled in the placebo group, received 318 
maltodextrins. Maltodextrixins, even at higher doses, are commonly used as placebo in clinical 319 
trials (44,45). Contrasting data suggest that maltodetrins could influence gut microbiota 320 
composition and immune system (46-48). Here we did not observe significant changes in the gut 321 
microbiota composition, fecal butyrate levels and innate and acquired immunity biomarkers in 322 
children entrolled in the placebo group, which supports the use of maltodextrins in placebo 323 
treatments. 324 
In conclusion, although additional research should be focused on the specific molecular 325 
mechanisms involved, we have shown that FM-CBA L74 induces positive regulation of the mutual 326 
interaction between the immune system and gut microbiota.  327 
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Figure legends 485 
Figure 1. Oscillospira and Faecalibacterium levels. Box plots showing the abundance of 486 
Oscillospira and Faecalibacteriumin the studied population at baseline (t0) and after 3 months of 487 
treatment (t3) with fermented milk (Milk) and placebo (PL). Boxes represent the interquartile range 488 
(IQR) between the first and third quartiles, and the line inside represents the median (2nd quartile). 489 
Whiskers denote the lowest and the highest values within 1.5 x IQR from the first and third 490 
quartiles, respectively. Asterisks indicate a significant difference as obtained by pairwise Wilcoxon 491 
test (P<0.05). 492 
Figure 2. Lachnospiraceae and Ruminococcaceae abundance correlates with innate and 493 
acquired immunity. Heatplot showing Spearman’s correlations between genera belonging to 494 
Lachnospiraceae and Ruminococcaceaeand levels of immunity biomarkers. Rows and columns are 495 
clustered by Euclidean distance and Ward linkage hierarchical clustering. The intensity of the 496 
colours represents the degree of association, as measured by Spearman’s correlations. Only genera 497 
occurring in at least 20% of the samples were included. Asterisks indicate a significant correlation 498 
after Benjamini & Hochberg correction. 499 
Figure 3. Faecal butyrate concentration. Box plots showing the abundance of faecal butyratein 500 
the study population at baseline (t0) and after 3 months of treatment (t3) with fermented milk 501 
(Milk) and placebo (PL). Asterisks indicate a significant difference as obtained by pairwise 502 
Wilcoxon test (P<0.05).See Figure 1 legend for a description of the box plots. 503 
 504 
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Table 1. Composition of the study dietary products.  
 Groups 
Value for 100 gr of product Cow’s milk fermented with 
L. paracasei CBA L74 (MILK) Placebo (PL) 
Energy, kcal 367 388 
Proteins, gr 24.0 0 
Carbohydrates, gr 66.4 97 
Fats, gr 0.6 0 
Lactobacillus paracasei CBA L74, CFU* 5.9 x 1011 - 
*killed bacteria 
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Table 2. Main anamnestic, demographic and immunological features of the study population. 
 
 
Groups 
 
Cow’s milk fermented 
with L. paracasei CBA 
L74 (MILK) 
Placebo (PL) 
 
N.  10 10 
Male, n (%)  8 (80) 5 (50) 
Age, m (SD)  34.3 (8.9) 37.2 (8.7) 
Breastfeeding, n (%)  10 (100) 7 (70) 
Duration of breastfeeding, m (SD) 6.2 (5.9) 10 (6.6) 
Weight at t0, kg (SD) 15.7 (3.3) 14.9 (2.2) 
Weight at t3, kg (SD) 16.1 (2.8) 15.6 (2.4) 
Height at t0, cm (SD) 95.9 (8.5) 95.7 (6.2) 
Height at t3, cm (SD)  97.6 (7.6) 98 (6.1)  
Alfa-defensin at t0, (SD) 1.5 (1.4) 1.2 (1.2) 
Alfa-defensin at t3, (SD) 4.2 (1.9) 1.6 (1.3) 
Beta-defensin 2 at t0, (SD) 28.7 (25.1) 32.3 (13.2) 
Beta-defensin 2 at t3, (SD) 46.8 (21.1) 38.6 (15) 
LL-37 at t0, (SD) 13.3 (6.9) 16 (9.3) 
LL-37 at t3, (SD) 32 (16.3) 19.4 (14.5) 
sIgA at t0, (SD) 24.1 (9.9) 30.8 (18.2) 
sIgA at t3, (SD) 42.8 (14) 32.5 (16.4) 
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